[18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer

Oral Oncology

Volumn 45, Issue 12, 2009, Pages

  Been, Lukas B ^a   Hoekstra, Harald J ^a   Suurmeijer, Albert J H ^a   Jager, Pieter L ^a   van der Laan, Bernard F A M ^a   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

18F FDG PET; 18F FLT PET; Laryngeal cancer; Positron emission tomography; Radiotherapy; Therapy evaluation

Indexed keywords

FLUORODEOXYGLUCOSE F 18; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HASHIMOTO DISEASE; HUMAN; LARYNX CANCER; MALE; PRIORITY JOURNAL; COMPARATIVE STUDY; EVALUATION; FEASIBILITY STUDY; LARYNX TUMOR; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; DIDEOXYNUCLEOSIDES; FEASIBILITY STUDIES; FLUORODEOXYGLUCOSE F18; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 70449517261     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.07.008     Document Type: Article

References (25)

1. McGuirt W.F., Greven K.M., Keyes Jr. J.W., et al. Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol 104 4 Pt 1 (1995) 274-278
2. Fu K.K., Woodhouse R.J., Quivey J.M., Phillips T.L., and Dedo H.H. The significance of laryngeal edema following radiotherapy of carcinoma of the vocal cord. Cancer 49 4 (1982) 655-658
3. Terhaard C.H., Bongers V., van Rijk P.P., and Hordijk G.J. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 23 11 (2001) 933-941
4. Greven K.M., Williams III D.W., Keyes Jr. J.W., McGuirt W.F., Watson Jr. N.E., and Case L.D. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?. Cancer J Sci Am 3 6 (1997) 353-357
5. Oe A., Kawabe J., Torii K., et al. Detection of local residual tumor after laryngeal cancer treatment using FDG-PET. Ann Nucl Med 21 1 (2007) 9-13
6. Schwartz D.L., Rajendran J., Yueh B., et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130 12 (2004) 1361-1367
7. Strauss L.G. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23 10 (1996) 1409-1415
8. van der Putten L., Hoekstra O.S., de Bree R., et al. 2-Deoxy-2[F-18]FDG-PET for detection of recurrent laryngeal carcinoma after radiotherapy: interobserver variability in reporting. Mol Imaging Biol 10 5 (2008) 294-303
9. Brouwer J., Hooft L., Hoekstra O.S., et al. Systematic review: accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. Head Neck 30 7 (2008) 889-897
10. Jager P.L., Vaalburg W., Pruim J., de Vries E.G., Langen K.J., and Piers D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42 3 (2001) 432-445
11. de Boer J.R., van der Laan B.F., Pruim J., et al. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas. Eur J Nucl Med Mol Imaging 29 9 (2002) 1182-1187
12. Wedman J., Pruim J., Langendijk J.A., and van der Laan B.F. Visualization of small glottic laryngeal cancer using methyl-labeled (11)C-methionine positron emission tomography. Oral Oncol (2009)
13. 18F]FLT). J Radioanal Nucl Ch 243 (2000) 843-846
14. 18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27 2 (1986) 235-238
15. Lonneux M., Borbath I., Bol A., et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med 26 6 (1999) 591-598
16. Lowe V.J., Kim H., Boyd J.H., Eisenbeis J.F., Dunphy F.R., and Fletcher J.W. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-d-glucose PET imaging. Radiology 212 3 (1999) 799-802
17. 18F-fluorodeoxyglucose, 123I-alpha-methyl-l-tyrosine and 99mTc-hexakis-2-methoxyisobutylisonitrile. Eur J Nucl Med Mol Imaging 29 3 (2002) 324-330
18. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31 12 (2004) 1659-1672
19. Eriksson S., Kierdaszuk B., Munch-Petersen B., Oberg B., and Johansson N.G. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 176 2 (1991) 586-592
20. Bardot V., Dutrillaux A.M., Delattre J.Y., et al. Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. Br J Cancer 70 2 (1994) 212-218
21. Cole P.D., Smith A.K., and Kamen B.A. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol 50 2 (2002) 111-116
22. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45 4 (2004) 695-700
23. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48 5 (2007) 726-735
24. Been L.B., Elsinga P.H., de Vries J., et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 32 1 (2006) 39-43
25. 18F-fluorodeoxyglucose-positron emission tomography. Chest 129 2 (2006) 393-401